Highlights
- Sales over the Year and quarter: The company experienced a substantial growth of 9.9 % in the past year, substantial increase in net sales/revenue by 4.47 %.
- Income over the Year and quarter: There has been decline in other income over the past year which is -360.04 %, Marginal decrease of -667.8% in other income during this quarter.
- Profit over the Year and quarter: Challenges in sustaining profitability for STRIDES PHARMA SCIENCE LIMITED. Profit dropped by -175.7 % Year to Year, STRIDES PHARMA SCIENCE LIMITED’s profitability dropped by -80.68 % Quarter to Quarter.
- EPS over the Year and quarter: EPS declined by -286.79 % Year to Year. EPS decreased by -63.54 % in previous quarter. Analysis needed for shareholder value.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 986.37 Cr | Rs. 1037.668 Cr | Rs. 1084.035 Cr | + 4.47 % | + 9.9 % |
Expenses | Rs. 830.81 Cr | Rs. 843.86 Cr | Rs. 854.3 Cr | + 1.24 % | + 2.83 % |
Operating Profit | Rs. 155.56 Cr | Rs. 193.81 Cr | Rs. 229.74 Cr | + 18.54 % | + 47.69 % |
OPM % | 15.77 % | 18.68 % | 21.19 % | + 2.51 % | + 5.42 % |
Other Income | Rs. -13.49 Cr | Rs. 10.93 Cr | Rs. -62.06 Cr | -667.8 % | -360.04 % |
Interest | Rs. 80.52 Cr | Rs. 79.28 Cr | Rs. 80.16 Cr | + 1.11 % | -0.45 % |
Depreciation | Rs. 60.93 Cr | Rs. 51.23 Cr | Rs. 49.76 Cr | -2.87 % | -18.33 % |
Profit before tax | Rs. 0.62 Cr | Rs. 74.23 Cr | Rs. 37.76 Cr | -49.13 % | + 5990.32 % |
Tax % | 20.91 % | 16.3 % | 24.62 % | + 8.32 % | + 3.71 % |
Net Profit | Rs. -13.8 Cr | Rs. 54.06 Cr | Rs. 10.44 Cr | -80.69 % | + 175.65 % |
EPS in Rs | Rs. -1.06 | Rs. 5.42 | Rs. 1.98 | -63.47 % | + 286.79 % |
Today, we’re looking at STRIDES PHARMA SCIENCE LIMITED’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a robust year-over-year sales growth of 9.9 %. However, it did see a marginal increase of 4.47 % from the previous quarter. Expenses ticked up slightly by 1.24 % quarter-on-quarter, aligning with the annual rise of 2.83 %. Operating profit, while up 47.69 % compared to last year, faced a quarter-on-quarter increase of 18.54 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 5.42 %, but an expansion of 2.51 % sequentially. Other income fell by -667.8 % compared to the last quarter, despite an annual decline of -360.04 %. Interest expenses surged remarkably by 1.11 % from the previous quarter, yet the year-over-year decrease remains at a moderate -0.45 %. Depreciation costs fell by -2.87 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -18.33 %. Profit before tax grew annually by 5990.32 % but saw a reduction from the preceding quarter by -49.13 %.
Tax expenses as a percentage of profits increased slightly by 3.71 % compared to last year, with a more notable quarter-on-quarter increase of 8.32 %. Net profit rose by 175.65 % year-on-year but witnessed a -80.69 % contraction from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 286.79 % but a quarterly fall of -63.47 %. In summary, STRIDES PHARMA SCIENCE LIMITED’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
---|---|---|---|---|---|
Sales | Rs. 986.37 Cr | Rs. 1037.668 Cr | Rs. 1084.035 Cr | + 4.47 % | + 9.9 % |
Expenses | Rs. 830.81 Cr | Rs. 843.86 Cr | Rs. 854.3 Cr | + 1.24 % | + 2.83 % |
Operating Profit | Rs. 155.56 Cr | Rs. 193.81 Cr | Rs. 229.74 Cr | + 18.54 % | + 47.69 % |
Net Profit | Rs. -13.8 Cr | Rs. 54.06 Cr | Rs. 10.44 Cr | -80.69 % | + 175.65 % |
EPS in Rs | Rs. -1.06 | Rs. 5.42 | Rs. 1.98 | -63.47 % | + 286.79 % |
In reviewing STRIDES PHARMA SCIENCE LIMITED’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 9.9 % year-on-year growth, however, there was a minor increase of 4.47 % from the previous quarter. Expenses rose by 2.83 % compared to the previous year, with a 1.24 % increase quarter-on-quarter. Operating Profit surged by 47.69 % annually, and saw a 18.54 % increase from the last quarter.
Net Profit showed yearly increase of 175.65 %, and experienced a -80.69 % decrease from the previous quarter. Earnings Per Share (EPS) rose by 286.79 % annually, however dipped by -63.47 % compared to the last quarter. In essence, while STRIDES PHARMA SCIENCE LIMITED exhibits strong annual growth indicators, short-term fluctuations suggest the need for agile strategies to navigate market dynamics effectively. That’s all for now in the financial sector.